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A B S T R A C T   
Liver damage involves oxidative stress and a progression from chronic hepatitis to hepatocellular carcinoma 
(HCC). The increased incidence of liver disease in Egypt and other countries in the last decade, coupled with poor 
prognosis, justify the critical need to introduce alternative chemopreventive agents that may protect against liver 
damage. The aim of this study was to evaluate the efficacy of exopolysaccharide-peptide (PSP) complex extracted 
from Pleurotus ostreatus as a hepatoprotective agent against diethylnitrosamine (DEN)/carbon tetrachloride 
(CCL4)-induced hepatocellular damage in rats. The levels of liver injury markers (ALT, AST and ALP) were 
substantially increased following DEN/CCl4 treatment. DEN/CCl4 - induced oxidative stress was confirmed by 
elevated levels of lipid peroxidation and decreased levels of superoxide dismutase, glutathione-S-transferase, and 
reduced glutathione. PSP reversed these alterations in the liver and serum, and provided protection evidenced by 
reversal of histopathological changes in the liver. The present study demonstrated that PSP extract from 
P. ostreatus exhibited hepatoprotective and antioxidant effects against DEN/CCl4-induced hepatocellular damage 
in rats. Given the high prevalence of HCV-related liver damage in Egypt, our results suggest further clinical 
evaluation of P. ostreatus extracts and their potential hepatoprotective effects in patients with liver disease.   
1. Introduction 
Medicinal mushrooms have been shown to stimulate immune func-
tion, contribute to glucose homoeostasis and to modulate detoxification, 
as well as exert anti-inflammatory, and anticancer activities (reviewed 
in Ref. [1]). They are rich sources of antioxidants such as thiamine 
(vitamin B1), riboflavin (vitamin B2), nicotinic acid (vitamin B3), biotin 
and ascorbic acid (vitamin C) [2], as well as carotenoids, polyphenolic 
compounds and flavonoids, which prevent free radical damage and 
reduce the risk of chronic diseases [3]. The genus Pleurotus comprises 
about 40 species, that are commonly referred to as ‘‘oyster mushrooms”. 
Pleurotus ostreatus extracts have been shown to exhibit hypolipidemic [3, 
4], immunostimulant, antiproliferative and antitumor activities [5,6], as 
well as anti-inflammatory, antioxidant [7–9], and antifungal activities 
[10]. 
Extracts from P. ostreatus, such as polysaccharide-peptide complex 
(PSP), possess hepatoprotective properties against liver damage caused 
by toxic chemicals. Aqueous extracts contain high concentrations of 
cysteine, methionine and aspartic acid. They improve the antioxidant 
status and were shown to revert hepatic damage [7,9]. Treatment of rats 
with polysaccharides from the P. ostreatus mycelium are reported to 
protect against carbon tetrachloride (CCl4)-induced hepatic damage 
[11]. 
Liver damage involves oxidative stress and generally a progression 
from steatosis to chronic hepatitis, fibrosis, cirrhosis and hepatocellular 
carcinoma (HCC) [12]. Egypt has one of the highest global burdens of 
hepatitis C virus (HCV) infection, with an estimated 10% in people be-
tween 15 and 59 years of age, and thousands die every year of the 
consequences of HCV, such as liver cirrhosis and HCC [13]. 
The antioxidant enzymes catalase (CAT), superoxide dismutase 
(SOD) and glutathione peroxidase (Gpx) act in concert to protect cellular 
components from damage by free radicals [14,15]. The reduction of 
their activity is associated with the accumulation of oxidants, leading to 
loss of integrity and function of cell membranes, contributing to cell 
injury. GSH is an important non-enzymatic antioxidant which promotes 
the detoxification of several toxic metabolites. The depletion of GSH 
* Corresponding author. 103 Borough Rd, London, SE1 0AA, United Kingdom. 
E-mail address: aleeme2@lsbu.ac.uk (E. Aleem).  
Contents lists available at ScienceDirect 
Biochemistry and Biophysics Reports 
journal homepage: www.elsevier.com/locate/bbrep 
https://doi.org/10.1016/j.bbrep.2020.100852 
Received 29 March 2020; Received in revised form 25 September 2020; Accepted 29 October 2020   
Biochemistry and Biophysics Reports 24 (2020) 100852
2
promotes generation of reactive oxygen species (ROS) and oxidative 
stress with a cascade of effects thereby affecting functional as well as 
structural integrity of cell and organelle membranes [16]. The GSTs are 
a multigene family of isozymes that catalyse the conjugation of GSH to a 
variety of electrophilic compounds, and thereby exert a critical role in 
cellular protection against ROS [17]. 
Liver injury results in an increase in serum concentrations of alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST). Both 
aminotransferases are highly concentrated in the liver. Alkaline phos-
phatase (ALP), another indicator of liver damage, is mainly derived from 
the liver and bones in healthy adults [18]. An increase in serum ALP 
levels is frequently associated with a variety of diseases, such as extra-
hepatic bile obstruction, intrahepatic cholestasis, infiltrative liver dis-
ease and hepatitis [19]. 
The increased incidence of liver disease in Egypt in the last decade, 
coupled with the poor prognosis, justify the critical need to introduce 
alternative chemopreventive agents that may protect against liver 
damage. We have previously shown that β-glucans extracted in our labs 
from the inedible mushroom Schizophylum commune reduced the inci-
dence of HCC in dimyethyl-benz [a]anthracene (DMBA)-treated mice 
and this effect was coupled with an increase in apoptosis [20]. Using a 
similar approach, the aims of the present study were (1) to extract crude 
polysaccharo peptide complex (PSP) from P. ostreatus, and (2) to study 
its potential hepatoprotective and antioxidant effects in an experimental 
model of DEN/CCl4-induced hepatotoxicity in rats. 
2. Materials and methods 
2.1. Preparation of the mushroom extract by fermentation 
Pure mycelia of Pleurotus ostreatus were obtained from the Agricul-
tural Research Center (Giza, Egypt). The culture was maintained on 
potato-dextrose agar (PDA) and sub-cultured every month. The mush-
room extract was prepared according to [21] (supplementary data). 
Total protein and total sugar contents were determined by Lowry 
method [22] using BSA as standard and by phenol sulfuric acid method 
[23] using glucose as standard, respectively. 
2.2. Spectroscopy and nuclear magnetic resonance 
Ultraviolet and infrared absorptions were determined as described in 
[20]. The 1H and 13C nuclear magnetic resonance (NMR) spectroscopy 
was performed according to the method described by [24]. NMR spectra 
were obtained using a 500 MHz JEOL spectrometer (Japan). 
2.3. Animals 
Male albino Wistar rats were purchased from the National Research 
Center for biological products (Cairo, Egypt). Animal care and the 
experimental protocols were in accordance with the guidelines of the 
National Institutes of Health guide for the care and use of Laboratory 
animals (NIH Publications No. 8023, revised 1978). Five animals were 
housed per cage and kept on standard diet (mouse chow) and water ad 
libitum, 22 ◦C room temperature (RT), 50 ± 10% humidity and 12-h 
light/dark cycle. The food was withdrawn 18–24 h before the 
experiment. 
2.4. Induction of hepatotoxicity and experimental animal groups 
Forty-Eight male albino Wistar rats weighing 100–150 g were 
randomly divided into six groups of eight rats each (Fig. 1). Group I 
received only saline solution intraperitoneal (i.p). Groups II, III and IV 
each received one dose of 200 mg/kg body weight of DEN. After 2 weeks 
of DEN administration, hepatotoxicity was promoted through subcu-
taneous (Sc) injections of CCl4 (3 ml/kg/week) for 6 weeks [25]. Group 
II served as positive (toxin) control. In order to study whether early 
administration of PSP would have a protective effect against DEN/CCl4 
hepatoxicity, Group III received PSP extract at a dose of 30 mg/kg body 
weight, 3 times/week, i.p for 2 weeks before DEN administration and for 
the remaining 12 weeks of the experiment. The PSP dose was selected 
based on a preliminary acute toxicity test (Table S1). Group IV received 
30 mg/kg body weight of PSP, 3 times/week, i.p for the last 4 weeks of 
the experiment after DEN/CCl4 treatment. Group V: Served as a control 
group for group III and received the same PSP dose for 14 weeks. Group 
VI: Served as a control group for group IV and received the same PSP 
dose for the last 4 weeks of the experiment. 
2.5. Cell culture and cell viability 
HepG2 cell line (DSMZ, Braunschweig, Germany) was cultured in 
RPMI 1640 (Gibco, Paisley, UK) with 10% fetal bovine serum, penicillin 
(100 units/ml), streptomycin (50 μg/ml) (Hyclone, Logan, UT) at 37 ◦C 
in a humidified atmosphere containing 5% CO2 and confirmed 
authentic using Short Tandem Repeat kit AmpFSTR identifier (Applied 
Biosystems, Foster City, CA). HepG2 cells were plated in 96-well plates 
at 104 cells/well and treated after 24 h with serial dilutions of the crude 
partially soluble PSP in DMSO. Cell viability was assessed after 48 h PSP 
exposure using Sulforhodamine B (SRB) stain. 
Fig. 1. Experimental groups: Group 1 was treated with saline, group II with DEN/CCL4 at the doses shown, group III received PSP at the dose shown for 14 weeks, 
group IV received the same dose of PSP for 4 weeks after administration of DEN/CCL4. Groups V and VI served as PSP controls for groups III and IV, respectively. 
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2.6. Tissue sampling and biochemical assays 
Animals were subjected to mild ether anesthesia following overnight 
fast, blood was collected from the abdominal aorta and the serum was 
separated by centrifugation and stored at − 80 ◦C for evaluation of the 
following parameters using commercially available kits (Biosystem S.A., 
Spain): ALT, AST and ALP. Whole blood was collected in EDTA-coated 
tubes and used for the determination of WBCs, RBCs and Hb. Cells 
were analyzed using a flow cytometry-based Advia 2120 Hematology 
system. The liver was washed twice with ice-cold saline. A portion of the 
liver was homogenized (10%, w/v) in ice-cold sodium potassium 
phosphate buffer (0.01 M, pH 7.4) containing 1.15% KCl. The homog-
enate was centrifuged at 10,000×g for 20 min at 4 ◦C, and the super-
natant was used for the determination of: LPO [26]; SOD [27]; GSH 
[28]; and GST activity [29]. 
2.7. Histopathology 
Liver sections were cut immediately, fixed in 10% neutral buffered 
formalin, processed, and embedded in paraffin. Sections (4–5 μm) were 
prepared and mounted on glass slides and stained with hematoxylin and 
eosin (H&E) for histopathological evaluation. 
2.8. Statistical analyses 
Data were expressed as mean ± SD for 8 rats per group. Comparison 
between the means of various treatment groups was analyzed using least 
significant difference (LSD) test. A value of p < 0.05 was considered 
significant. Statistical analysis was performed using the SPSS statistical 
package version 16.00 (SPSS Inc, Chicago, Illinois, USA). 
3. Results 
3.1. Extraction and structural analysis of the exopolysaccharide-peptide 
(PSP) complex from Pleurotus ostreatus 
Ethanol precipitation of PSP and its elemental analysis, as well as 
results from IR and 13C NMR are shown in the supplementary data 
(Figs. S1–7). The partially soluble PSP had a total carbohydrate content 
of 88.85% and 5.3% of soluble protein. 
3.2. PSP extract is cytotoxic to HepG2 liver cancer cell line 
The viability of the human liver cancer cell line (HepG2) was 
measured after the addition of increasing concentrations of PSP (0, 1, 
2.5, 5 and 10 μg/ml DMSO) for 48 h (Fig. 2). The IC50 was inferred from 
the graph to be 0.5 μg/mL. 
3.3. Effect of PSP extract on serum biomarkers of liver damage 
Administration of DEN/CCL4 induced liver damage but no liver tu-
mors were observed. Hepatotoxicity was confirmed by histopathology. 
Treatment with DEN/CCL4 induced a significant 6-fold increase in 
serum ALT levels compared to control indicating liver damage (Group 
II). Administration of PSP to groups III and IV significantly reduced 
serum ALT levels almost back to normal. A similar pattern of results was 
obtained for other serum biomarkers; a significant 2- and 1.5-fold in-
crease in AST and ALP levels, respectively, was observed in group II 
animals, compared to all other experimental groups. This effect was 
reversed upon treatment with PSP extract (Group III, IV). There was no 
significant difference in ALT, AST or ALP levels between groups III, IV, V 
and VI compared to negative control (Group I) or between groups III and 
V, or IV and VI, respectively (Table 1). 
3.4. Effect of PSP extract on oxidative stress biomarkers 
Treatment of rats with DEN/CCL4 resulted in a 1.4-fold significant 
increase in the level of hepatic lipid peroxidation (LPO) compared to 
group I. Administration of PSP to groups III and IV resulted in a signif-
icant decrease in hepatic LPO levels by 1.6- and 1.5-fold, respectively, 
compared to group II rats. 
A highly significant decrease in hepatic LPO was shown in group V 
that received only PSP for the 14 weeks of the experiment (control group 
for group III) compared to groups I, II and III. However, the level of 
hepatic LPO did not show any significant difference in rats receiving PSP 
only for 4 weeks (Group VI) when compared to either group IV or to 
group I rats (Table 2). 
Administration of DEN/CCl4 (Group II) resulted in a significant 
decrease in both serum and hepatic SOD, as well as in hepatic GST ac-
tivity compared to their corresponding values in the negative control 
group I rats. Administration of PSP reversed this effect in groups III and 
IV (Table 3). 
The activity of both serum SOD and hepatic GST in groups III and IV, 
which received PSP either before or after the hepatotoxins, did not show 
any significant change compared to the corresponding values in group I 
rats. Serum SOD in group V rats that served as control for group III and 
received PSP for 14 weeks, showed highly significant increase compared 
to rats of both group I and group III (Table 3). 
DEN/CCl4 treated group (Group II) showed a significant 2.7-fold 
decrease in the level of hepatic GSH compared to the hepatic GSH in 
the control group I. Administration of PSP in groups III and IV reversed 
this effect resulting in hepatic GSH concentrations approaching that in 
the control group I (Table 3). 
3.5. PSP extract increases WBCs, RBCs and haemoglobin concentration 
in rats treated with DEN/CCl4 
DEN/CCl4 caused a significant decrease in WBCs and RBCs count as 
well as in the hemoglobin (Hb) levels in group II rats compared to all 
other groups (Table 4). Treatment with PSP significantly alleviated this 
hematotoxicity, bringing RBCs count and Hb levels to levels approxi-
mating those of control group I rats. 
3.6. Histopathology 
Liver sections from control rats (Group I) showed normal arrange-
ment of hepatocytes (Fig. 3A). Rats treated with DEN/CCL4 (Group II) 
showed mild portal mononuclear inflammatory infiltrate, fibrosis, lytic 
necrosis, frequent apoptotic bodies and distended portal veins. Steatosis 
manifest by marked accumulation of lipids (Fig. 3B), as well as 
dysplastic hepatocytes with karyomegaly and prominent macronucleoli 
(Fig. 3C) were also evident. Group III rats showed more or less normal 
liver architecture (Fig. 3D), however, rats post-treated with PSP (Group 
IV), showed minimal portal inflammatory infiltrate (Fig. 3E). Groups V Fig. 2. Cytotoxicity of PSP extract from P. ostreatus in HepG2 cell line.  
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and VI treated only with PSP showed minimal changes (Fig. 3F and G). 
4. Discussion 
Despite significant advances in surgical treatments and locoregional 
therapies, prognosis is still poor for patients with liver disease, and for 
those with recurrent hepatocellular carcinoma (HCC). Therefore, che-
moprevention, and lifestyle changes are important as a supportive 
approach for the protection from liver disease. Most cases of HCC in 
humans develop in the setting of chronic liver disease, characterized by 
inflammation, cirrhosis, fibrosis and steatosis [30]. In the present study 
we used the DEN/CCl4-model to mimic liver damage. This disease model 
can be used for studying fibrogenesis and HCC [31]. The goal of this 
study was to characterize the in vivo putative hepatoprotective and 
antioxidant effects of P. ostreatus rather than it’s anticancer activity. The 
present study demonstrated that the exopolysaccharide peptide complex 
(PSP), isolated from P. ostreatus exhibited hepato-, haemato-protective, 
and antioxidant activities in DEN/CCl4-treated rats. 
Furthermore, PSP extract was cytotoxic in the human liver cancer 
cell line HepG2. These results are consistent with those of [32] in human 
colorectal and leukaemia cell lines, with [33] against gastric cancer in 
vitro and in vivo, and with [34] in HepG2, HCT 116 and HeLa cell lines. 
Additionally, previous reports demonstrated that extracts from 
P. ostreatus suppressed proliferation of breast cancer (MCF-7, 
MDA-MB-231) and colon cancer (HT-29, HCT-116) cells, without 
affecting proliferation of epithelial mammary MCF-10A and normal 
colon FHC cells [5]. In a similar study [35], showed that the normal liver 
cell line WRL-68 was more resistant than the liver cancer cell lines 
(Huh7, HepG2, SMMC-7721 and Hep3B) to the cytotoxic effects of a 
polysaccharide-protein (PSP) complex isolated from Pleurotus pulmo-
narius. Protein extracts from P. ostreatus were found to induce apoptosis 
in SW480 cells through ROS production, GSH depletion and mitochon-
drial dysfunction [32]. 
DEN and CCl4 generate reactive oxygen species (ROS), which cause 
cellular injury [15]. In the present study, DEN/CCl4 increased serum 
ALT, AST and ALP levels concomitant with histopathological modifi-
cations in the liver reflecting the induction of acute hepatotoxicity and 
hepatic structural damage [25,36]. PSP reduced ALT, AST and ALP ac-
tivities suggesting a potential reversal of liver injury, accompanied with 
an improved histomorphology of the liver. This is consistent with pre-
vious work by Refs. [7,36] on P. ostreatus extracts, by Ref. [37] on 
silymarin, and by Ref. [38] on silymarin and Anji white tea polyphenols. 
Bioactivation of DEN and CCl4 by cytochrome P450 system in the 
liver yields highly reactive free radicals that can react with proteins or 
lipids, or abstract a hydrogen atom from an unsaturated lipid, thus 
initiating lipid peroxidation [36,37]. Free radical scavenging enzymes 
such as SOD, CAT, GPx and GST are the first line of defence against 
oxidative injury. The inhibition of antioxidant system may cause the 
accumulation of H2O2 or products of its decomposition [17]. In the 
present study, the exposure to DEN/CCl4 resulted in increased levels of 
hepatic lipid peroxides and depleted hepatic SOD, GST activity as well as 
reduced GSH concentration. PSP extract-treated animals showed a sig-
nificant reduction in the levels of hepatic oxidation markers with 
concomitant amelioration in the hepatic antioxidant defence system, 
Table 1 
PSP extract reverses the hepatotoxic effect of DEN/CCl4 on ALT, AST and ALP levels.  
Experimental Groups Group I Group II Group III Group IV Group V Group VI 
ALT (U/L) 
(mean ± SD) 
39.57 ± 2.60 243.20 ± 84.73 45.83 ± 2.63 34.90 ± 4.68 36.15 ± 3.80 30.09 ± 3.74 
F (p) 35.254* (<0.001) 
P1  <0.001* 0.757 0.818 0.866 0.640 
P2  <0.001* <0.001* <0.001* <0.001* 
P3   0.633  
P4  0.812 
AST (U/L) 
(mean ± SD) 
158.67 ± 18.75 338.67 ± 103.56 190.17 ± 21.85 139.00 ± 19.96 177.17 ± 29.46 145.50 ± 11.24 
F (p) 15.469* (<0.001) 
p1  <0.001* 0.249 0.469 0.496 0.627 
p2  <0.001* <0.001* <0.001* <0.001* 
p3   0.631  
p4  0.810 
ALP (U/L) 
(mean ± SD) 
168.33 ± 48.14 268.83 ± 26.41 186.17 ± 62.37 198.00 ± 20.79 192.50 ± 19.09 179.83 ± 57.65 
F (p) 4.174* (0.005) 
p1  <0.001* 0.477 0.240 0.337 0.646 
p2  0.002* 0.008* 0.004* 0.001* 
p3   0.800  
p4  0.469 
F: F test (ANOVA), p1: p value of LSD test between negative control and other groups, p2: p value of LSD test between group II and group III, IV, V and VI, p3: p value of 
LSD test between group III and group V, p4: p value of LSD test between group IV and group VI, *: Statistically significant at p ≤ 0.05. 
Table 2 
PSP extract reduces hepatic lipid peroxidation in rats treated with DEN/CCl4.  
Experimental Groups Group I Group II Group III Group IV Group V Group VI 
LPO (nmol/g liver) 
(mean ± SD) 
153.02 ± 27.58 217.03 ± 18.81 134.28 ± 20.72 147.19 ± 18.04 105.39 ± 20.38 144.43 ± 8.25 
F (p) 20.746* (<0.001) 
p1  <0.001* <0.112 0.614 <0.001* <0.458 
p2  <0.001* <0.001* <0.001* <0.001* 
p3   0.002*  
p4  0.268 
F: F test (ANOVA), p1: p value of LSD test between negative control and other groups, p2: p value of LSD test between group II and group III, IV, V and VI, p3: p value of 
LSD test between group III and group V, p4: p value of LSD test between group IV and group VI, *: Statistically significant at p ≤ 0.05. 
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which could be related to its ability to scavenge ROS, thus preventing 
further damage to membrane lipids. Among the antioxidant compounds 
in the oyster mushroom are polyphenols, which can act as hydrogen 
donors, to neutralize ROS and inhibit the formation of O2- and OH-, the 
main inducers of lipid peroxidation [39]. Our results are in agreement 
with reports by Refs. [14] showing the antioxidant effects of a PSP 
complex extracted from P. abalonus-fruiting bodies on 
senescence-accelerated mice. Similar results were reported by Ref. [40] 
using Paraquat as liver damage inducer. 
In the present study, the decrease in haematological parameters 
(WBCs, RBCs and Hb), in DEN/CCl4-treated rats, is in agreement with 
[41]. The destruction of RBCs reflects the abnormality in hepatocellular 
functions and potential changes in the membrane cholesterol and 
phospholipid ratio. One of potential mechanism of DEN/CCl4 -induced 
hemolysis is oxidative stress induction as reflected in this study by 
increased lipid peroxidation. This effect is similar to the effect of 
cadmium-induced haematological toxicity [42]. The administration of 
PSP caused an amelioration of the haematological parameters (WBCs; 
RBCs count & Hb level) probably through lowering lipid peroxidation 
levels in cell membranes; leading to decreased haemolysis of RBCs 
and/or due to the prevention of free radicals induced damage. Similar 
results were reported by Ref. [43]. The increase in WBCs counts in the 
present study may be due to an activation of immune response [44] as 
reported by Ref. [45] that polysaccharides from P ostreatus induced 
Table 3 
Effect of PSP extract on serum and hepatic superoxide dismutase (SOD), hepatic glutathione -S- transferase (GST) activities, and GSH concentration.  
Experimental Groups Group I Group II Group III Group IV Group V Group VI 
Serum SOD (mean ± SD) 7.72 ± 2.33 5.84 ± 0.83 6.62 ± 0.99 6.84 ± 0.98 10.23 ± 1.54 8.47 ± 1.09 
F (p) 7.619* (<0.001) 
p1  0.026* 0.180 0.285 0.004* 0.357 
p2  0.342 0.222 <0.001* 0.003* 
p3   <0.001*  
p4  0.052 
Hepatic SOD (mean ± SD) 1.16 ± 0.07 0.68 ± 0.05 0.81 ± 0.04 0.89 ± 0.13 0.93 ± 0.15 1.00 ± 0.16 
F (p) 13.241* (<0.001) 
p1  <0.001* <0.001* <0.001* 0.001* 0.017* 
p2  0.045* 0.003* <0.001* <0.001* 
p3   0.077  
p4  0.089 
Hepatic GST (mean ± SD) 2.76 ± 0.71 1.44 ± 0.30 2.34 ± 0.68 2.24 ± 0.42 2.86 ± 0.64 3.05 ± 0.36 
F (p) 6.890* (<0.001) 
p1  <0.001* 0.183 0.107 0.757 0.372 
p2  0.008* 0.016* <0.001* <0.001* 
p3   0.104  
p4  0.016* 
GSH (mg/g liver) 
(mean ± SD) 
115.36 ± 51.18 43.01 ± 11.89 100.58 ± 22.26 83.38 ± 11.20 109.85 ± 40.46 89.55 ± 31.43 
F (p) 4.077* (0.006) 
p1  <0.001* 0.425 0.090 0.765 0.168 
p2   0.013* 0.035* 0.001* 0.016 
p3     0.616  
p4      0.738 
F: F test (ANOVA). 
p1: p value of LSD test between negative control and other groups. 
p2: p value of LSD test between group II and group III, IV, V and VI. 
p3: p value of LSD test between group III and group V. 
p4: p value of LSD test between group IV and group VI. 
*: Statistically significant at p ≤ 0.05. 
Table 4 
PSP extract increases white (WBCs), red (RBCs) cells’ counts and hemoglobin (Hb) concentration in rats treated with DEN/CCl4.  
Experimental Groups Group I Group II Group III Group IV Group V Group VI 
WBCs count (#*103/L) 
(mean ± SD) 
11.40 ± 3.54 6.70 ± 1.14 16.65 ± 7.23 11.73 ± 2.63 16.24 ± 3.00 15.98 ± 3.17 
F (p) 5.165* (0.003) 
p1  0.076 0.062 0.904 0.069 0.084 
p2  0.001* 0.060 0.001* 0.001* 
RBCs count (#*106/L) 
(mean ± SD) 
7.78 ± 0.22 4.88 ± 0.95 7.45 ± 0.42 7.63 ± 0.59 7.51 ± 0.33 7.75 ± 0.55 
F (p) 18.600* (<0.001) 
p1  <0.001* 0.424 0.696 0.485 0.932 
p2  <0.001* <0.001* <0.001* <0.001* 
Hb (g/dl) 
(mean ± SD) 
12.78 ± 1.44 7.92 ± 1.63 10.93 ± 0.63 11.32 ± 0.83 11.98 ± 0.81 12.25 ± 0.64 
F (p) 12.151* (<0.001) 
p1  <0.001* 0.025* 0.058 0.286 0.501 
p2  <0.001* <0.001* <0.001* <0.001* 
F: F test (ANOVA). 
p1: p value of LSD test between negative control and other groups. 
p2: p value of LSD test between group II and group III, IV, V and VI. 
*: Statistically significant at p ≤ 0.05. 
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NK-cell mediated cytotoxicity against lung and breast cancer cells 
mediated by NKG2D and IFNγ upregulation. 
The present study has some limitations in the fact that the active 
component in the polysaccharide-peptide complex (PSP) extract from 
P. ostreatus has not been identified. Extracts contain several compounds, 
and future research should focus on isolation and characterization of the 
active therapeutic compound in the PSP extract. Additionally, although 
our goal, in the present study, was to investigate the hepatoprotective 
effects of PSP against liver injury, it would have been relevant to 
investigate it’s antineoplastic effects on HCC, as well. Future preclinical 
studies should be directed towards studying the interaction of PSP with 
conventional chemo- and radiotherapy, as well as with targeted therapy 
in liver and other types of malignancies. 
5. Conclusion 
In conclusion, this study confirms that extracts from locally available 
oyster mushroom (P. ostreatus) have hepatoprotective, and antioxidant 
effects against liver damage induced in rats by DEN/CCL4. Hence, it is 
recommended to invest in the commercial cultivation of oyster mush-
room in Egypt for nutritional and medicinal purposes. Since Egypt is one 
of the countries with high prevalence of hepatitis C infection, our results 
suggest further clinical evaluation of P. ostreatus and its potential hep-
atoprotective effects in patients with liver disease. 
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